AstraZeneca Launches USD 40m Early-Stage Anti-Infectives R&D Unit – GEN News

AstraZeneca will spin-off its anti-infectives R&D unit

test-214185_1280AstraZeneca will spend USD 40 million to create a new stand-alone subsidiary focused on early-stage research and development of small molecule anti-infectives. AstraZeneca is one of the big Pharma, together with Roche, that is focusing on the development of new solutions for drug-resistant bacteria. Read more

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s